Wealth Enhancement Advisory Services’s Cardiff Oncology CRDF Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.1K	Buy	+12,095	New	+$19.2K	﹤0.01%	4060

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Wealth Enhancement Advisory Services's CRDF Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Cardiff Oncology (CRDF) in Q2 2026: 12,095 shares worth $16.1K. The stake represents ﹤0.01% of the portfolio and ranks #4060 among its holdings.

105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

Wealth Enhancement Advisory Services held 12,095 shares of Cardiff Oncology worth $16.1K as of Q2 2026.
Cardiff Oncology was a new Wealth Enhancement Advisory Services position in Q2 2026.
Cardiff Oncology made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #4060 holding.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.